Treatment-induced changes of lymphocyte subsets in patients with adenoid cystic carcinoma of the head and neck.
Adult
Aged
B-Lymphocytes
/ metabolism
Biomarkers, Tumor
/ blood
Carcinoma, Adenoid Cystic
/ blood
Case-Control Studies
Female
Flow Cytometry
Head and Neck Neoplasms
/ blood
Humans
Lymphocyte Count
Lymphocytes, Tumor-Infiltrating
/ metabolism
Male
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
T-Lymphocytes
/ metabolism
Tumor Microenvironment
Adenoid cystic carcinoma
B cells
CCR7
CD73
PD-1
T cells
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
30
10
2018
accepted:
23
02
2019
pubmed:
1
3
2019
medline:
14
6
2019
entrez:
1
3
2019
Statut:
ppublish
Résumé
Adenoid cystic carcinoma (ACC) of the head and neck is a rare and highly malignant tumor, characterized by perineural growth and early distant metastases. The composition of immune cells in the peripheral blood and the tumor microenvironment is critical to tumor growth and control. However, little is known about the frequency and function of the relevant immune cell subsets in this entity. In ACC patients (n = 11) and matched healthy donors (n = 11), the frequency of peripheral blood T and B cells was measured by flow cytometry at different treatment stages of disease (24 samples). Cells were further characterized by their expression of CCR7, PD-1, CD39 and CD73. Tumor-infiltrating lymphocytes (TIL) were analyzed by immunohistochemistry for ten patients and for three patients by flow cytometry. CD4 Composition of lymphocyte subgroups behaves similar to squamous cell carcinoma in the head and neck, except for T
Identifiants
pubmed: 30815724
doi: 10.1007/s00405-019-05363-2
pii: 10.1007/s00405-019-05363-2
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1465-1473Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SCHU 2536/3
Références
Cancer Res. 2001 Nov 1;61(21):7889-99
pubmed: 11691809
Mol Immunol. 2005 May;42(7):799-809
pubmed: 15829268
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7
pubmed: 16916931
PLoS One. 2006 Dec 27;1:e129
pubmed: 17205133
Oral Oncol. 2009 Oct;45(10):e167-74
pubmed: 19576838
PLoS One. 2009 Jul 29;4(7):e6412
pubmed: 19641607
Am J Clin Oncol. 2011 Feb;34(1):76-81
pubmed: 20177363
J Immunol. 2010 Jul 1;185(1):134-43
pubmed: 20498355
J Immunol Methods. 2011 Jun 30;369(1-2):59-68
pubmed: 21513715
Eur J Immunol. 2012 Jul;42(7):1876-85
pubmed: 22585562
Clin Cancer Res. 2013 Feb 15;19(4):889-99
pubmed: 23363813
Blood. 2013 Jul 4;122(1):9-18
pubmed: 23678003
AIDS. 2013 Jun 19;27(10):1545-55
pubmed: 24005375
Head Neck Pathol. 2014 Mar;8(1):88-109
pubmed: 24037641
Clin Cancer Res. 2013 Dec 1;19(23):6585-96
pubmed: 24097865
Cancer Res. 2015 Feb 1;75(3):508-518
pubmed: 25480946
Oral Oncol. 2015 Jul;51(7):652-61
pubmed: 25943783
Int J Clin Exp Pathol. 2015 Jul 01;8(7):8227-35
pubmed: 26339391
Oncotarget. 2015 Nov 10;6(35):37117-34
pubmed: 26359351
Cancer Prev Res (Phila). 2016 Apr;9(4):265-74
pubmed: 26862087
Int Immunol. 2016 Aug;28(8):383-91
pubmed: 26989092
Clin Cancer Res. 2016 Aug 15;22(16):4236-48
pubmed: 27034329
Cancer Immunol Res. 2016 Aug;4(8):679-87
pubmed: 27312343
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Oncotarget. 2017 Jul 4;8(27):44418-44433
pubmed: 28574843
Onco Targets Ther. 2017 Jun 13;10:2983-2992
pubmed: 28652780
Oncotarget. 2017 Dec 20;9(5):5834-5847
pubmed: 29464038
Pathologe. 2018 Nov;39(6):532-538
pubmed: 30350175
Cancer Res. 1997 Jul 1;57(13):2602-5
pubmed: 9205063
Int Arch Allergy Immunol. 1997 Sep;114(1):38-45
pubmed: 9303329